Australia Respiratory Devices Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia respiratory devices market is a recurring-revenue business in which masks, filters, tubing and circuits are replaced far more often than machines. Sleep apnoea therapy forms the largest product family, while ventilators, high-flow systems and oxygen equipment add hospital and home capacity, and inhalation devices serve a large asthma and COPD population.

Three forces shape the outlook: wider diagnosis and home testing of sleep and lung disease, an older population that needs long-term oxygen and ventilatory support, and tighter regulator scrutiny of device safety and supply quality.

In June 2025, the Therapeutic Goods Administration began Federal Court action against Philips Electronics Australia over sleep and breathing devices. In November 2025, Lung Foundation Australia called for earlier COPD testing, and in August 2026 ResMed reported annual revenue of USD 5.65 billion.

Key Market Trends and Insights

• Sleep therapy scale: On 30 October 2025, ResMed reported quarterly revenue of USD 1,335.6 million, up 9%, with devices at USD 680.3 million and masks and other products at USD 489.1 million.
• Hospital strength: On 26 May 2026, Fisher & Paykel Healthcare reported hospital revenue of NZ$1.51 billion, up 18%, with hospital consumables growing 16% in the year to March 2026.
• Undiagnosed COPD: In November 2025, Lung Foundation Australia said roughly half a million Australians live with COPD, more than half are unaware of it, and one in 13 people over 40 is affected.
• Regulatory scrutiny: In June 2025, the Therapeutic Goods Administration alleged more than 44,000 instances of unlawful supply of Philips sleep and breathing devices that did not meet Australian safety requirements.

Australia Respiratory Devices Market Size and Forecast

The market is moving from equipment sales towards connected, consumable-led care, as home testing, remote monitoring and comfort-focused masks widen access to treatment. Sleep apnoea therapy devices remain the largest product family, with diagnostic and monitoring devices advancing fastest. Home care leads end users while aged care facilities grow quickest, and COPD outpaces other applications. New South Wales is the largest region and Queensland the fastest growing. Safety oversight, local service depth and wider screening underpin a steady mid-single-digit outlook.

Key Takeaways: Australia Respiratory Devices Market

Steady Mid-Single-Digit Expansion

Revenue is on course to expand by about 69% across the decade, from AUD 850.00 million in 2025 to AUD 1,438.22 million in 2035 at a 5.4% CAGR. Mask, circuit and filter replacement makes demand repeat-driven.

Diagnosis Drives the Fastest Growth

Diagnostic and monitoring devices grow at an estimated 6.8% CAGR and aged care facilities at an estimated 6.5% CAGR through 2035. COPD, the fastest-growing application at 5.9%, gains from calls for earlier spirometry testing.

Safety and Service Shape Buying Decisions

Regulatory action and supplier results across 2025 and 2026 have placed device safety, local service and supply continuity at the centre of hospital and home care procurement.

• Federal Court action against Philips Electronics Australia reported in June 2025
• ResMed revenue of USD 5.65 billion in the year to June 2026
• Roughly half a million Australians live with COPD, many undiagnosed

Australia Respiratory Devices Market Report Summary

Key Insight

Wider diagnosis of sleep and lung disease, an older population and recurring consumable replacement support steady value growth. Sleep therapy leads, while diagnostics and aged care advance fastest.

Key Trends in the Australia Respiratory Devices Market

The Australia respiratory devices market is being shaped by wider COPD and sleep apnoea detection, hospital-led demand for high-flow care and sharper regulatory scrutiny of device safety.

August 2026 - SomnoMed Reports Modest Growth and a Leadership Change

• On 28 August 2026, ASX-listed SomnoMed reported revenue of AUD 114.5 million for the year to June 2026, up 2.7%, with EBITDA of AUD 10.9 million.
• Karen Borg was appointed chief executive after a co-chief executive resigned in late July 2026.
• The company began a controlled global release of Virtus, an oral appliance for sleep apnoea patients who also grind their teeth.

May 2026 - Fisher & Paykel Healthcare Reports Hospital-Led Growth

• On 26 May 2026, the company reported revenue of NZ$2.31 billion for the year to March 2026, up 14%, and net profit of NZ$468.5 million, up 24%.
• Homecare revenue reached NZ$802.7 million, up 8%, while sleep apnoea mask revenue rose 7%.
• The F&P Solo and F&P Nova mask ranges drove mask growth, and new applications consumables grew 18%.

November 2025 - Lung Foundation Australia Urges Earlier COPD Testing

• On 26 November 2025, chief executive Mark Brooke urged anyone with ongoing breathlessness or a persistent cough to ask a GP for a spirometry test.
• Lung Foundation Australia said about half a million people live with COPD and more than half do not know it.
• One in 13 people over 40 is affected, which supports demand for spirometers, inhalers, oxygen and ventilatory support.

June 2025 - TGA Takes Philips Electronics Australia to Federal Court

• Reported on 4 June 2025, the Therapeutic Goods Administration alleged that foam in CPAP, BiPAP and AVAPS machines could degrade and be inhaled.
• It also alleged that replacement silicone foam in the Trilogy 100 ventilator could dislodge and block the airway.
• The regulator said it was not alleging wrongdoing by hospitals or health practitioners.

Key Insight

Detection, safety and hospital demand pull in the same direction. Earlier diagnosis lifts treatment volumes, while regulatory scrutiny rewards suppliers with proven quality systems, local service and dependable remediation.

Recent Market Developments in the Australia Respiratory Devices Market

Recent developments, presented from the most recent, show the Australia respiratory devices market moving through strong supplier results, new mask and oxygen product releases and portfolio restructuring.

August 2026 - ResMed Closes a Strong Fiscal Year and Plans to Sell Software

• On 6 August 2026, ResMed reported fiscal year revenue of USD 5.65 billion, up 10%, with a GAAP gross margin of 61.1%.
• It agreed to sell its MatrixCare software business, with closing expected in the first quarter of its next fiscal year.
• Product releases included AirCurve 11 ST and ST-A in the United States and AirTouch F30i Comfort in Brazil and Chile.

August 2026 - Inogen Grows International Sales of Oxygen Concentrators

• On 6 August 2026, Inogen reported second quarter revenue of USD 95.1 million, up 3.0%.
• International sales rose 14.8% to USD 41.3 million, while United States sales and rentals declined.
• The Rove 6 portable concentrator launched in Canada, and enrolment in the Simeox H SCOPE study in China was completed.

January 2026 - Fisher & Paykel Healthcare Launches F&P Nova Nasal in the United States

• The F&P Nova Nasal mask launched in the United States in January 2026, extending the F&P Nova range.
• The Nova and Solo ranges drove sleep apnoea mask revenue growth of 7% in the year to March 2026.
• Mask launches in large export markets influence the designs offered to Australian sleep clinics.

October 2025 - ResMed Reports Quarterly Growth and Launches Sleep Institute

• On 30 October 2025, ResMed reported first quarter revenue of USD 1,335.6 million, up 9%, with a GAAP gross margin of 61.5%.
• The AirTouch N30i nasal mask received dual Red Dot Product Design awards for 2025.
• ResMed launched the Sleep Institute, a clinical insights initiative that debuted at World Sleep Congress 2025.

Key Insight

Recent events show suppliers refining portfolios, releasing new masks and concentrators and posting resilient results. Competitive attention is shifting to comfort, connected care and dependable supply.

Australia Respiratory Devices Industry Segmentation

The Expert Market Research’s report on the Australia Respiratory Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Sleep Apnoea Therapy Devices
• Oxygen Therapy Devices
• Ventilators and High-Flow Systems
• Nebulisers and Inhalation Devices
• Diagnostic and Monitoring Devices
• Others

Sleep Apnoea Therapy Devices lead revenue, with ResMed reporting USD 5.65 billion of revenue in August 2026 and Fisher & Paykel Healthcare citing 7% mask growth in May 2026. Oxygen Therapy Devices rely on stationary and portable concentrators, and Inogen's international sales rose 14.8% in its August 2026 report. Ventilators and High-Flow Systems benefit from 16% hospital consumables growth. Nebulisers and Inhalation Devices serve asthma and COPD patients. Diagnostic and Monitoring Devices grow fastest at an estimated 6.8% CAGR as spirometry and home sleep testing widen. Others covers oral appliances, airway clearance and accessories.

Market Breakup by Application

• Sleep Apnoea
• COPD
• Asthma
• Critical and Acute Respiratory Failure
• Others

Sleep Apnoea leads applications and was the focus of the Therapeutic Goods Administration's June 2025 Federal Court action over Philips CPAP and BiPAP devices. COPD grows fastest at an estimated 5.9% CAGR, as Lung Foundation Australia urged earlier spirometry in November 2025 for roughly half a million affected people. Asthma depends on inhalers, spacers and nebulisers and grows steadily. Critical and Acute Respiratory Failure draws on ventilators and high-flow therapy, where Fisher & Paykel Healthcare reported 18% hospital revenue growth in May 2026. Others covers bronchiectasis, cystic fibrosis and paediatric breathing disorders.

Market Breakup by End User

• Home Care Settings
• Hospitals and Intensive Care Units
• Aged Care Facilities
• Sleep and Diagnostic Clinics
• Others

Home Care Settings lead, as CPAP machines, concentrators and nebulisers are used daily by patients at home, and Fisher & Paykel Healthcare's homecare revenue rose 8% in the year to March 2026. Hospitals and Intensive Care Units follow, supported by its 16% hospital consumables growth reported in May 2026. Aged Care Facilities grow fastest at an estimated 6.5% CAGR, as an older population needs oxygen and ventilatory support. Sleep and Diagnostic Clinics expand with home sleep testing, and SomnoMed's August 2026 results show continued demand for oral appliance alternatives.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates through the largest patient base and Sydney-linked sleep device manufacturing and distribution, growing at an estimated 5.0% CAGR through 2035. Victoria follows at 5.2%, with Melbourne teaching hospitals anchoring ventilator and high-flow demand. Queensland is the fastest-growing region at an estimated 6.2%, helped by population inflow and retirees. Western Australia grows at 5.6%, supported by remote oxygen delivery needs. South Australia grows at 5.4%. Others covers Tasmania, the Australian Capital Territory and the Northern Territory at 5.3%, where Lung Foundation Australia's November 2025 call for earlier testing stresses access.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Respiratory Devices Market

Competition spans global sleep and respiratory groups, New Zealand and Australian specialists, hospital equipment makers and oxygen service providers. Barriers include regulatory approval, clinical evidence, service networks and relationships with sleep clinics and hospitals.

ResMed

ResMed, headquartered in San Diego and listed on the Australian Securities Exchange, makes CPAP and BiPAP devices, masks and connected sleep software, with Australian manufacturing at Bella Vista in Sydney. On 6 August 2026 it reported revenue of USD 5.65 billion for the year to June 2026, up 10%, and agreed to sell its MatrixCare software business. In October 2025 its AirTouch N30i mask received dual Red Dot Product Design awards.

Fisher & Paykel Healthcare

Fisher & Paykel Healthcare, headquartered in Auckland, New Zealand, supplies sleep apnoea masks, hospital humidification and high-flow oxygen systems to Australian hospitals and homes. For the year to March 2026 it reported revenue of NZ$2.31 billion, up 14%, with hospital revenue up 18%. The F&P Solo and F&P Nova mask ranges drove mask growth, and F&P Nova Nasal launched in the United States in January 2026.

Philips

Royal Philips, headquartered in Amsterdam, supplies sleep and respiratory care in Australia through Philips Electronics Australia Limited, including Respironics CPAP and BiPAP machines and the Trilogy ventilator. In June 2025 the Therapeutic Goods Administration began Federal Court proceedings alleging unlawful supply of devices with degrading or dislodging foam, with more than 44,000 alleged instances. The matter keeps procurement attention on device safety and remediation.

Inogen

Inogen, headquartered in Beverly, Massachusetts, makes portable and stationary oxygen concentrators, including the Rove 6, and the Simeox airway clearance system. On 6 August 2026 it reported second quarter revenue of USD 95.1 million, up 3.0%, with international sales up 14.8% to USD 41.3 million. Enrolment in the Simeox H SCOPE study is complete, with results expected in the second half of 2026.

Other players operating in the Australia respiratory devices market include SomnoMed, Air Liquide Healthcare Australia, Getinge, Dräger, and BOC Healthcare, alongside independent medical equipment distributors, pharmacies, sleep clinics and home oxygen service providers supplying devices and consumables across Australia.

Key Insight

Competition rests on regulatory approval, clinical evidence, service reach and clinic relationships rather than price alone. Global groups hold scale, while specialists compete through comfort and local support.